Chalfont St. Giles, UK – 22 January 2014 – GE Healthcare (NYSE:GE), today announced that biopharmaceutical company Nanotherapeutics, Inc. has selected GE Healthcare Life Sciences' FlexFactory™ biomanufacturing platform to perform a central role in its Advanced Development and Manufacturing (NANO-ADM) Center at Alachua, Florida, USA. Construction of the NANO-ADM Center, which began in October 2013, is expected to be complete in early 2015.
The NANO-ADM Center will fulfill a U.S. Department of Defense contract awarded to Nanotherapeutics in April 2013 to enable faster and more effective development of biomedical countermeasures designed to protect and treat U.S. military personnel against chemical, biological, radiological and nuclear attacks, in addition to protecting against outbreaks of naturally occurring, emerging and genetically engineered infectious diseases. Following a competitive tender, GE Healthcare has become part of a network of 16 partners, and has been closely involved from the inception of the project, through the contract application process, and on into the construction phase.
Nanotherapeutics’ adoption of GE’s FlexFactory biomanufacturing platform and single-use technologies will help significantly reduce commissioning time and allow rapid reconfiguration of the facility for the manufacture of different products as and when required. GE’s team of experts in biopharmaceutical manufacturing will provide full training and support in process development to the NANO-ADM Center staff, further accelerating set-up time.
Nigel Darby, Vice President Bioprocess and GE Officer said, “We are delighted to be playing a pivotal role in the establishment and set-up of Nanotherapeutics’ Advanced Development and Manufacturing Center. The wide-ranging and forward-looking criteria of this U.S. Department of Defense contract demands a fast and responsive solution and the flexibility of our established FlexFactory manufacturing platform and the deep sector experience of our team will both be critical components in the success of the program. Being selected by the industry experts at Nanotherapeutics is a clear indication of our reputation as a trusted partner in technologies for biopharmaceutical manufacturing and in process development.”
Notes to Editors
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics. The Company has one FDA cleared injectable biologic, NanoFUSE® DBM used by orthopedic surgeons as bone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation and expertise in pre-clinical and clinical product development as well as clinical trial management to support its products. Established in 1999, the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates. For more information, visit the Company website at www.nanotherapeutics.com.
Issued for and on behalf of GE Healthcare.
To contact the GE Healthcare team at College Hill, email GE-Bioprocess@collegehill.com
Tim WatsonAssociate Partner